Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor
暂无分享,去创建一个
D. Costagliola | P. Giral | D. Bonnefont-Rousselot | M. Valantin | R. Bittar | L. Assoumou | É. Aslangul | M. Federspiel | C. Cherfils | O. Kalmykova
[1] D. Costagliola,et al. Determinants of Low-Density Lipoprotein Particle Diameter during Antiretroviral Therapy Including Protease Inhibitors in HIV-1-Infected Patients , 2012, Antiviral therapy.
[2] Mardge H. Cohen,et al. HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study , 2010, AIDS.
[3] D. Costagliola,et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial , 2010, AIDS.
[4] N. Bogavac-Stanojević,et al. Small, dense LDL cholesterol and apolipoprotein B: relationship with serum lipids and LDL size. , 2009, Atherosclerosis.
[5] A. Oguz,et al. Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. , 2009, Journal of atherosclerosis and thrombosis.
[6] M. Gentile,et al. Efficacy and safety of rosuvastatin in the management of dyslipidemia , 2009, Vascular health and risk management.
[7] C. Grunfeld. Understanding the complications of antiretroviral drugs. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] M. Trip,et al. Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia. , 2008, The Journal of pediatrics.
[9] M. Rizzo,et al. The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins , 2006, Cardiovascular Drugs and Therapy.
[10] M. Rizzo,et al. Low-density lipoprotein size and cardiovascular risk assessment. , 2006, QJM : monthly journal of the Association of Physicians.
[11] C. Sirtori,et al. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. , 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[12] André R Miserez,et al. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. , 2005, Metabolism: clinical and experimental.
[13] C. Packard,et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. , 2003, Atherosclerosis.
[14] J. Cristol,et al. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? , 2003, Atherosclerosis.
[15] D. Freedman,et al. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. , 2002, The American journal of cardiology.
[16] D. Freedman,et al. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. , 2002, Atherosclerosis.
[17] Y. Friedlander,et al. Low density lipoprotein particle size and risk factors of insulin resistance syndrome. , 2000, Atherosclerosis.
[18] M. Austin,et al. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. , 1993, Atherosclerosis.
[19] R. Krauss,et al. Detection and quantitation of LDL subfractions , 1992 .
[20] E. Gong,et al. Characterization of human high-density lipoproteins by gradient gel electrophoresis. , 1981, Biochimica et biophysica acta.